Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

Online Appendices

Files in this Data Supplement:

Appendix 1: Utility decrements for modelled health states
Appendix 2: Management costs of diabetes-related complication states
Appendix 3: Calculation of net monetary benefit
Appendix 4: Relative impact from mixed treatment comparison meta-analysis of alternative second-line therapy compared with metformin monotherapy for glycosylated hemoglobin, overall hypoglycemia and body weight
Appendix 5: Cumulative incidence of long-term diabetesrelated complications of second-line therapies over a 40-year period, reference case analysis (%)
Appendix 6: Ranking of treatment strategies in sensitivity and scenario analysis for net monetary benefit* at willingness-to-pay threshold of $50,000 per quality-adjusted life year